 | • レポートコード：QYR9N7884 • 出版社/出版日：QYResearch / 2019年6月14日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（受注後２～3営業日） • 産業分類：医療・製薬・バイオ |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当資料は、原発性硬化性胆管炎のグローバル市場について調査・分析したレポートで、種類別（タイプI、タイプII）、用途別（病院、診療所、その他）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含まれています。 ・原発性硬化性胆管炎の世界市場規模 ・主要企業別市場シェア ・原発性硬化性胆管炎の世界市場規模：種類別（タイプI、タイプII） ・原発性硬化性胆管炎の世界市場規模：用途別（病院、診療所、その他） ・原発性硬化性胆管炎のアメリカ市場規模（種類別、用途別） ・原発性硬化性胆管炎のヨーロッパ市場規模（種類別、用途別） ・原発性硬化性胆管炎の中国市場規模（種類別、用途別） ・原発性硬化性胆管炎の日本市場規模（種類別、用途別） ・原発性硬化性胆管炎の東南アジア市場規模（種類別、用途別） ・原発性硬化性胆管炎のインド市場規模（種類別、用途別） ・原発性硬化性胆管炎の中南米市場規模（種類別、用途別） ・主要企業別分析（企業概要、製品動向、販売量など） ・原発性硬化性胆管炎の世界市場予測（2019年-2025年） ・原発性硬化性胆管炎の地域別市場予測（2019年-2025年） ... |
Primary sclerosing cholangitis (PSC) is a condition causing long-term inflammation and scarring (fibrosis) of bile ducts in the liver. These ducts are tubes that allow the liquid (bile) produced by the liver to pass through the intestine allowing fat digestion. This disease predominantly affects men between the age of 25 and 40 years. The damage to the ducts causes accumulation of bile acids, essential components of bile to build up in the liver leading to liver tissue damage, portal hypertension (high blood pressure in the vessels connecting the liver and the gut), and liver failure, and may increase the risk of liver cancer.Requirement of providing affordable treatment, owing to high costs associated with liver transplantation coupled with increasing risk factors resulting in the development of serious disorders are major factors that are expected to increase the adoption of PSC drugs, in turn favoring market growth in the near future.
In 2018, the global Primary Sclerosing Cholangitis market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Primary Sclerosing Cholangitis status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Primary Sclerosing Cholangitis development in United States, Europe and China.
The key players covered in this study
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Shire Plc.
NGM Biopharmaceuticals, Inc.
Dr. Falk Pharma GmbH
Allergan Plc.
Conatus Pharmaceuticals, Inc.
Durect Corporation
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.
Market segment by Type, the product can be split into
Type I
Type II
Market segment by Application, split into
Hospital
Clinics
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Primary Sclerosing Cholangitis status, future forecast, growth opportunity, key market and key players.
To present the Primary Sclerosing Cholangitis development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Primary Sclerosing Cholangitis are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Primary Sclerosing Cholangitis Market Size Growth Rate by Type (2014-2025)
1.4.2 Type I
1.4.3 Type II
1.5 Market by Application
1.5.1 Global Primary Sclerosing Cholangitis Market Share by Application (2014-2025)
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Primary Sclerosing Cholangitis Market Size
2.2 Primary Sclerosing Cholangitis Growth Trends by Regions
2.2.1 Primary Sclerosing Cholangitis Market Size by Regions (2014-2025)
2.2.2 Primary Sclerosing Cholangitis Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Primary Sclerosing Cholangitis Market Size by Manufacturers
3.1.1 Global Primary Sclerosing Cholangitis Revenue by Manufacturers (2014-2019)
3.1.2 Global Primary Sclerosing Cholangitis Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Primary Sclerosing Cholangitis Market Concentration Ratio (CR5 and HHI)
3.2 Primary Sclerosing Cholangitis Key Players Head office and Area Served
3.3 Key Players Primary Sclerosing Cholangitis Product/Solution/Service
3.4 Date of Enter into Primary Sclerosing Cholangitis Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Primary Sclerosing Cholangitis Market Size by Type (2014-2019)
4.2 Global Primary Sclerosing Cholangitis Market Size by Application (2014-2019)
5 United States
5.1 United States Primary Sclerosing Cholangitis Market Size (2014-2019)
5.2 Primary Sclerosing Cholangitis Key Players in United States
5.3 United States Primary Sclerosing Cholangitis Market Size by Type
5.4 United States Primary Sclerosing Cholangitis Market Size by Application
6 Europe
6.1 Europe Primary Sclerosing Cholangitis Market Size (2014-2019)
6.2 Primary Sclerosing Cholangitis Key Players in Europe
6.3 Europe Primary Sclerosing Cholangitis Market Size by Type
6.4 Europe Primary Sclerosing Cholangitis Market Size by Application
7 China
7.1 China Primary Sclerosing Cholangitis Market Size (2014-2019)
7.2 Primary Sclerosing Cholangitis Key Players in China
7.3 China Primary Sclerosing Cholangitis Market Size by Type
7.4 China Primary Sclerosing Cholangitis Market Size by Application
8 Japan
8.1 Japan Primary Sclerosing Cholangitis Market Size (2014-2019)
8.2 Primary Sclerosing Cholangitis Key Players in Japan
8.3 Japan Primary Sclerosing Cholangitis Market Size by Type
8.4 Japan Primary Sclerosing Cholangitis Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Primary Sclerosing Cholangitis Market Size (2014-2019)
9.2 Primary Sclerosing Cholangitis Key Players in Southeast Asia
9.3 Southeast Asia Primary Sclerosing Cholangitis Market Size by Type
9.4 Southeast Asia Primary Sclerosing Cholangitis Market Size by Application
10 India
10.1 India Primary Sclerosing Cholangitis Market Size (2014-2019)
10.2 Primary Sclerosing Cholangitis Key Players in India
10.3 India Primary Sclerosing Cholangitis Market Size by Type
10.4 India Primary Sclerosing Cholangitis Market Size by Application
11 Central & South America
11.1 Central & South America Primary Sclerosing Cholangitis Market Size (2014-2019)
11.2 Primary Sclerosing Cholangitis Key Players in Central & South America
11.3 Central & South America Primary Sclerosing Cholangitis Market Size by Type
11.4 Central & South America Primary Sclerosing Cholangitis Market Size by Application
12 International Players Profiles
12.1 Acorda Therapeutics, Inc.
12.1.1 Acorda Therapeutics, Inc. Company Details
12.1.2 Company Description and Business Overview
12.1.3 Primary Sclerosing Cholangitis Introduction
12.1.4 Acorda Therapeutics, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.1.5 Acorda Therapeutics, Inc. Recent Development
12.2 Gilead Sciences, Inc.
12.2.1 Gilead Sciences, Inc. Company Details
12.2.2 Company Description and Business Overview
12.2.3 Primary Sclerosing Cholangitis Introduction
12.2.4 Gilead Sciences, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.2.5 Gilead Sciences, Inc. Recent Development
12.3 Intercept Pharmaceuticals, Inc.
12.3.1 Intercept Pharmaceuticals, Inc. Company Details
12.3.2 Company Description and Business Overview
12.3.3 Primary Sclerosing Cholangitis Introduction
12.3.4 Intercept Pharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.3.5 Intercept Pharmaceuticals, Inc. Recent Development
12.4 Shire Plc.
12.4.1 Shire Plc. Company Details
12.4.2 Company Description and Business Overview
12.4.3 Primary Sclerosing Cholangitis Introduction
12.4.4 Shire Plc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.4.5 Shire Plc. Recent Development
12.5 NGM Biopharmaceuticals, Inc.
12.5.1 NGM Biopharmaceuticals, Inc. Company Details
12.5.2 Company Description and Business Overview
12.5.3 Primary Sclerosing Cholangitis Introduction
12.5.4 NGM Biopharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.5.5 NGM Biopharmaceuticals, Inc. Recent Development
12.6 Dr. Falk Pharma GmbH
12.6.1 Dr. Falk Pharma GmbH Company Details
12.6.2 Company Description and Business Overview
12.6.3 Primary Sclerosing Cholangitis Introduction
12.6.4 Dr. Falk Pharma GmbH Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.6.5 Dr. Falk Pharma GmbH Recent Development
12.7 Allergan Plc.
12.7.1 Allergan Plc. Company Details
12.7.2 Company Description and Business Overview
12.7.3 Primary Sclerosing Cholangitis Introduction
12.7.4 Allergan Plc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.7.5 Allergan Plc. Recent Development
12.8 Conatus Pharmaceuticals, Inc.
12.8.1 Conatus Pharmaceuticals, Inc. Company Details
12.8.2 Company Description and Business Overview
12.8.3 Primary Sclerosing Cholangitis Introduction
12.8.4 Conatus Pharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.8.5 Conatus Pharmaceuticals, Inc. Recent Development
12.9 Durect Corporation
12.9.1 Durect Corporation Company Details
12.9.2 Company Description and Business Overview
12.9.3 Primary Sclerosing Cholangitis Introduction
12.9.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.9.5 Durect Corporation Recent Development
12.10 Sirnaomics, Inc.
12.10.1 Sirnaomics, Inc. Company Details
12.10.2 Company Description and Business Overview
12.10.3 Primary Sclerosing Cholangitis Introduction
12.10.4 Sirnaomics, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)
12.10.5 Sirnaomics, Inc. Recent Development
12.11 Shenzhen HighTide Biopharmaceuticals Ltd.
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
Table Primary Sclerosing Cholangitis Key Market Segments
Table Key Players Primary Sclerosing Cholangitis Covered
Table Global Primary Sclerosing Cholangitis Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Primary Sclerosing Cholangitis Market Size Market Share by Type 2014-2025
Figure Type I Figures
Table Key Players of Type I
Figure Type II Figures
Table Key Players of Type II
Table Global Primary Sclerosing Cholangitis Market Size Growth by Application 2014-2025 (Million US$)
Figure Hospital Case Studies
Figure Clinics Case Studies
Figure Other Case Studies
Figure Primary Sclerosing Cholangitis Report Years Considered
Table Global Primary Sclerosing Cholangitis Market Size 2014-2025 (Million US$)
Figure Global Primary Sclerosing Cholangitis Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Primary Sclerosing Cholangitis Market Size by Regions 2014-2025 (Million US$)
Table Global Primary Sclerosing Cholangitis Market Size by Regions 2014-2019 (Million US$)
Table Global Primary Sclerosing Cholangitis Market Share by Regions 2014-2019
Figure Global Primary Sclerosing Cholangitis Market Share by Regions 2014-2019
Figure Global Primary Sclerosing Cholangitis Market Share by Regions 2019
Table Market Top Trends
Table Global Primary Sclerosing Cholangitis Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Primary Sclerosing Cholangitis Market Share by Manufacturers (2014-2019)
Figure Global Primary Sclerosing Cholangitis Market Share by Manufacturers in 2018
Table Global Primary Sclerosing Cholangitis Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Primary Sclerosing Cholangitis Product/Solution/Service
Table Date of Enter into Primary Sclerosing Cholangitis Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Primary Sclerosing Cholangitis Market Size by Type (2014-2019) (Million US$)
Table Global Primary Sclerosing Cholangitis Market Size Share by Type (2014-2019)
Figure Global Primary Sclerosing Cholangitis Market Size Market Share by Type (2014-2019)
Table Global Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table Global Primary Sclerosing Cholangitis Market Size Share by Application (2014-2019)
Figure Global Primary Sclerosing Cholangitis Market Size Market Share by Application (2014-2019)
Figure Global Primary Sclerosing Cholangitis Revenue Market Share by Application in 2018
Figure United States Primary Sclerosing Cholangitis Market Size 2014-2019 (Million US$)
Table United States Key Players Primary Sclerosing Cholangitis Revenue (2018-2019) (Million US$)
Table United States Key Players Primary Sclerosing Cholangitis Market Share (2018-2019)
Table United States Primary Sclerosing Cholangitis Market Size by Type (2014-2019) (Million US$)
Table United States Primary Sclerosing Cholangitis Market Share by Type (2014-2019)
Table United States Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table United States Primary Sclerosing Cholangitis Market Share by Application (2014-2019)
Figure Europe Primary Sclerosing Cholangitis Market Size 2014-2019 (Million US$)
Table Europe Key Players Primary Sclerosing Cholangitis Revenue (2018-2019) (Million US$)
Table Europe Key Players Primary Sclerosing Cholangitis Market Share (2018-2019)
Table Europe Primary Sclerosing Cholangitis Market Size by Type (2014-2019) (Million US$)
Table Europe Primary Sclerosing Cholangitis Market Share by Type (2014-2019)
Table Europe Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table Europe Primary Sclerosing Cholangitis Market Share by Application (2014-2019)
Figure China Primary Sclerosing Cholangitis Market Size 2014-2019 (Million US$)
Table China Key Players Primary Sclerosing Cholangitis Revenue (2018-2019) (Million US$)
Table China Key Players Primary Sclerosing Cholangitis Market Share (2018-2019)
Table China Primary Sclerosing Cholangitis Market Size by Type (2014-20189) (Million US$)
Table China Primary Sclerosing Cholangitis Market Share by Type (2014-2019)
Table China Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table China Primary Sclerosing Cholangitis Market Share by Application (2014-2019)
Figure Japan Primary Sclerosing Cholangitis Market Size 2014-2019 (Million US$)
Table Japan Key Players Primary Sclerosing Cholangitis Revenue (2018-2019) (Million US$)
Table Japan Key Players Primary Sclerosing Cholangitis Market Share (2018-2019)
Table Japan Primary Sclerosing Cholangitis Market Size by Type (2014-2019) (Million US$)
Table Japan Primary Sclerosing Cholangitis Market Share by Type (2014-2019)
Table Japan Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table Japan Primary Sclerosing Cholangitis Market Share by Application (2014-2019)
Figure Southeast Asia Primary Sclerosing Cholangitis Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Primary Sclerosing Cholangitis Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Primary Sclerosing Cholangitis Market Share (2018-2019)
Table Southeast Asia Primary Sclerosing Cholangitis Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Primary Sclerosing Cholangitis Market Share by Type (2014-2019)
Table Southeast Asia Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Primary Sclerosing Cholangitis Market Share by Application (2014-2019)
Figure India Primary Sclerosing Cholangitis Market Size 2014-2019 (Million US$)
Table India Key Players Primary Sclerosing Cholangitis Revenue (2018-2019) (Million US$)
Table India Key Players Primary Sclerosing Cholangitis Market Share (2018-2019)
Table India Primary Sclerosing Cholangitis Market Size by Type (2014-2019) (Million US$)
Table India Primary Sclerosing Cholangitis Market Share by Type (2014-2019)
Table India Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table India Primary Sclerosing Cholangitis Market Share by Application (2014-2019)
Figure Central & South America Primary Sclerosing Cholangitis Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Primary Sclerosing Cholangitis Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Primary Sclerosing Cholangitis Market Share (2018-2019)
Table Central & South America Primary Sclerosing Cholangitis Market Size by Type (2014-2019) (Million US$)
Table Central & South America Primary Sclerosing Cholangitis Market Share by Type (2014-2019)
Table Central & South America Primary Sclerosing Cholangitis Market Size by Application (2014-2019) (Million US$)
Table Central & South America Primary Sclerosing Cholangitis Market Share by Application (2014-2019)
Table Acorda Therapeutics, Inc. Company Details
Table Acorda Therapeutics, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019) (Million US$)
Figure Acorda Therapeutics, Inc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Acorda Therapeutics, Inc. Recent Development
Table Gilead Sciences, Inc. Company Details
Table Gilead Sciences, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Gilead Sciences, Inc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Gilead Sciences, Inc. Recent Development
Table Intercept Pharmaceuticals, Inc. Company Details
Table Intercept Pharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Intercept Pharmaceuticals, Inc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Intercept Pharmaceuticals, Inc. Recent Development
Table Shire Plc. Company Details
Table Shire Plc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Shire Plc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Shire Plc. Recent Development
Table NGM Biopharmaceuticals, Inc. Company Details
Table NGM Biopharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure NGM Biopharmaceuticals, Inc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table NGM Biopharmaceuticals, Inc. Recent Development
Table Dr. Falk Pharma GmbH Company Details
Table Dr. Falk Pharma GmbH Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Dr. Falk Pharma GmbH Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Dr. Falk Pharma GmbH Recent Development
Table Allergan Plc. Company Details
Table Allergan Plc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Allergan Plc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Allergan Plc. Recent Development
Table Conatus Pharmaceuticals, Inc. Company Details
Table Conatus Pharmaceuticals, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Conatus Pharmaceuticals, Inc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Conatus Pharmaceuticals, Inc. Recent Development
Table Durect Corporation Company Details
Table Durect Corporation Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Durect Corporation Recent Development
Table Sirnaomics, Inc. Company Details
Table Sirnaomics, Inc. Revenue in Primary Sclerosing Cholangitis Business (2014-2019)(Million US$)
Figure Sirnaomics, Inc. Revenue Growth Rate in Primary Sclerosing Cholangitis Business (2014-2019)
Table Sirnaomics, Inc. Recent Development
Table Shenzhen HighTide Biopharmaceuticals Ltd. Company Details
Table Global Primary Sclerosing Cholangitis Market Size by Regions (Million US$) 2019-2025
Figure Global Primary Sclerosing Cholangitis Market Size Share by Regions (2019-2025)
Figure Global Primary Sclerosing Cholangitis Market Size Share by Regions in 2025
Figure United States Primary Sclerosing Cholangitis Market Size Forecast (2019-2025)(Million USD)
Figure Europe Primary Sclerosing Cholangitis Market Size Forecast (2019-2025)(Million USD)
Figure China Primary Sclerosing Cholangitis Market Size Forecast (2019-2025)(Million USD)
Figure Japan Primary Sclerosing Cholangitis Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Primary Sclerosing Cholangitis Market Size Forecast (2019-2025)(Million USD)
Figure India Primary Sclerosing Cholangitis Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Primary Sclerosing Cholangitis Market Size Forecast (2019-2025)(Million USD)
Table Global Primary Sclerosing Cholangitis Market Size by Product (2019-2025) (Million US$)
Figure Global Primary Sclerosing Cholangitis Market Size by Product (2019-2025)
Figure Global Primary Sclerosing Cholangitis Market Size by Product in 2025
Table Global Primary Sclerosing Cholangitis Market Size by Application (2019-2025) (Million US$)
Figure Global Primary Sclerosing Cholangitis Market Size by Application (2019-2025)
Figure Global Primary Sclerosing Cholangitis Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
世界の原発性胆管胆管炎の治療市場：市場規模・現状・予測 Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There…- 世界の院内感染診断市場：市場規模・現状・予測 In 2018, the global Hospital-acquired Infection Diagnostics market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025. This report focuses on the global Hospital-acquired Infection Diagnostics status, future forecast, growth opportunity, …
- 世界の病院のEMRシステム市場：市場規模・現状・予測 An electronic health record (EHR), or electronic medical record (EMR), is the systematized collection of patient and population electronically-stored health information in a digital format.In 2018, the global Hospital EMR Systems market size was xx million US$ and it is expected to reach xx million …
- 世界のエラストグラフィー市場：市場規模・現状・予測 Elastography is a medical imaging modality that maps the elastic properties and stiffness of soft tissue. The main idea is that whether the tissue is hard or soft will give diagnostic information about the presence or status of disease. For example, cancerous tumours will often be harder than the su…
- 世界の外来診療所市場：市場規模・現状・予測 The outpatient clinics has continued to play a significant role in management of the cognitive behavioral disorders. High-risk situations such as substance abuse, sexual offence, depression, obesity and obsessive-compulsive behavior is becoming a major concern in various countries. Management of hig…